about
Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease StatusSafety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach.Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin.Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis.Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series.Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review.The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study.Kawasaki disease: an epidemiological study in central Italy.Current therapeutic approaches to autoimmune chronic uveitis in children.What do cytokine profiles tell us about subsets of juvenile idiopathic arthritis?Glucocorticoids in the management of systemic juvenile idiopathic arthritis.Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium.Describing Kawasaki shock syndrome: results from a retrospective study and literature review.Pediatric Osteoporosis: Diagnosis and Treatment Considerations.T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies.Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.Prebiologic Therapy Tuberculosis Screening Experience in a Pediatric Rheumatology Center: TST and IGRA Are Both Necessary.Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults.Differentiating PFAPA syndrome from monogenic periodic fevers.Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series.Psoriatic juvenile idiopathic arthritis associated with uveitis: a case reportClinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.Multifocal lymphadenopathy associated with severe Kawasaki disease: a difficult diagnosis.Recurrent orbital pain and diplopia in a 12 year old boy.Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis.Identification of autoantibodies against inner ear antigens in a cohort of children with idiopathic sensorineural hearing loss.Bone mass predictors in a large cohort of children with juvenile idiopathic arthritis (JIA).Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.Coeliac disease in patients with Kawasaki disease. Is there a link?Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis.Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: Clinical and laboratory correlates of remission duration.Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis.Early predictors of juvenile sacroiliitis in enthesitis-related arthritis.Erratum to: Successful treatment with adalimumab for severe multifocal choroiditis and panuveitis in presumed (early-onset) ocular sarcoidosis.
P50
Q28821054-B07462EB-CEDF-4E99-B93B-690C7C3BE21CQ30575712-F59A50DD-DFA5-4297-947F-B40354395CFCQ34157346-2F262DB1-CC27-46D7-A7AF-87B8B0B5E60CQ34373660-2843B328-B414-4C4D-BB05-B75880A8B55BQ34447002-FDE6C10E-4155-4B9F-A13A-A6183F8BA888Q35150941-8AEB5F19-300A-42DB-8637-3129A7B2650EQ35551700-41D11EC4-EE49-4D09-94C3-F79CB0C20929Q35565943-2C396213-C776-41D6-8123-952ED14A0326Q35688798-384B26D8-E056-4DCE-AF1D-D965DE4465CCQ36127496-C2014C50-2691-474F-8EC6-13521DAF42E9Q36790385-7D3F4E41-C8C4-4082-A5E1-D28C3D4EDBA2Q37765693-32224F32-6106-4272-8657-6D4FE25C3EF7Q37975164-390DBC8B-FBF5-4A20-AC21-BD861127BE28Q38118210-3AC8C1CD-59B0-4AF0-A53E-6BCF1BD0F49FQ38202741-69722BBF-3967-4922-B194-3AD8B2FD9980Q38711172-BFF744E1-918C-412C-ABC6-CB56060EC964Q38829966-DA2259FD-73B0-4B97-BE15-B224B6C93339Q38845448-533BBDE3-3C3C-4AA4-96C9-F3B86B8D9CDAQ38921958-013F061A-4D7B-4E75-9C9D-8211EB78536BQ38957800-E0B9C790-9C1B-46F5-A60D-1CDC3CAABDF3Q40139654-A4CDA599-74D2-45C2-B1F0-FC73A900D7E2Q40296686-35C13881-078B-4CC2-B804-EEBC0B98290AQ40310083-009BDB20-7F21-47F0-BDAE-805C99DA0523Q40378741-0B477562-3A16-49BF-8D7F-C80CF574AA5FQ41031522-5AED56A1-B485-4F8F-8204-00670827702EQ41901169-A9DFE769-0160-4197-8B8A-D785A6592C11Q42075063-07E5725D-5E44-44F9-B955-6EF45AFEC7E9Q43050402-602D4643-094B-46EC-B4B7-38A2A2CD5CC9Q43051489-745D6040-6932-44E7-8E1E-F729437FD664Q43300189-8FCDB9AF-BAD1-4BD4-8A76-C00180D4C4F5Q44325395-68A4D622-0A2B-4DC1-8BA4-01FECBC54820Q45745894-461BF56D-4147-4D78-AEAF-54CC12AE68DEQ46448264-0492CAA9-F39A-4236-9ED5-16281B9374C6Q46897900-ECAC1B7B-EA96-4AF7-AE21-F1769547AB1EQ47668191-24D3F1E5-9AED-453B-AB1B-CCF33C87F455Q47873184-9923977A-CE4A-4307-8F2C-C2BD9D7DF9FDQ48351375-36980F17-57EA-49BB-91A9-26D99936B39DQ50759000-B7F3B846-9210-4412-9C20-F7424C8A2F85Q50785942-15BBD2EA-5B91-4196-81D9-9B2182EE00E5Q50855222-7CA22421-4492-47A7-8274-B206088F9E37
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gabriele Simonini
@ast
Gabriele Simonini
@en
Gabriele Simonini
@es
Gabriele Simonini
@nl
Gabriele Simonini
@sl
type
label
Gabriele Simonini
@ast
Gabriele Simonini
@en
Gabriele Simonini
@es
Gabriele Simonini
@nl
Gabriele Simonini
@sl
prefLabel
Gabriele Simonini
@ast
Gabriele Simonini
@en
Gabriele Simonini
@es
Gabriele Simonini
@nl
Gabriele Simonini
@sl
P106
P1153
6701786202
P31
P496
0000-0002-5919-4861